MEDS DataMeds AI, Inc.
Wholesale-Drugs, Proprietaries & Druggists' Sundries · Nasdaq · SEC CIK 2030763 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-77.5%
TTM net income YoY44.2%
TTM EPS YoY187.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-92.1%
Operating margin-548.1%
Net margin-564.8%
FCF margin—
EBITDA margin-523.7%
Returns
ROE-1,706.7%
ROA-94.8%
ROIC (approx.)-153.4%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets99.6%
Debt / equity—
Current ratio0.14x
Interest coverage-6.22x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-60.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.67M | $1.78M | $1.56M | $1.67M | $3.01M | $7.79M | $10.86M | $12.41M |
| Cost of revenue | $2.24M | $1.60M | $1.39M | $9.53M | $2.78M | $7.29M | $10.17M | $11.16M |
| Gross profit | $431,880 | $182,204 | $170,221 | -$7.86M | $231,012 | $505,752 | $692,641 | $1.25M |
| SG&A expense | $3.34M | $7.06M | $4.87M | $4.13M | $30.17M | $4.86M | $31.17M | $4.35M |
| Operating income | -$3.37M | -$7.35M | -$6.02M | -$25.35M | -$31.55M | -$5.50M | -$31.35M | -$3.75M |
| Interest expense | $2.25M | $1.56M | $2.07M | $875,719 | $1.43M | $1.18M | $1.09M | $689,186 |
| Pretax income | $10.54M | -$18.36M | -$7.74M | -$27.85M | -$34.32M | -$6.67M | -$32.43M | -$4.33M |
| Net income | $10.59M | -$18.36M | -$7.74M | -$27.85M | -$34.32M | -$6.67M | -$32.43M | -$4.33M |
| EBITDA | -$3.02M | -$6.99M | -$5.66M | -$24.55M | -$30.75M | -$4.70M | -$30.55M | -$3.10M |
| EPS (basic) | 3.29 | -7.13 | -0.07 | — | -23.07 | -5.40 | -0.62 | — |
| EPS (diluted) | 2.72 | -7.13 | -0.07 | — | -23.07 | -5.40 | -0.62 | — |
| Weighted avg. shares (diluted) | 3.96M | 2.57M | 104.62M | — | 1.49M | 1.24M | 51.92M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $476,598 | $2.46M | $51,730 | $42,571 | $4.23M | $419,942 | $2.52M | $1.03M |
| Receivables | $1.97M | $1.17M | $992,147 | $1.14M | — | — | — | — |
| Inventory | $1.44M | $1.51M | $1.71M | $1.64M | $7.49M | $9.03M | $9.73M | $9.52M |
| Current assets | $5.22M | $5.63M | $2.76M | $2.82M | $12.82M | $13.51M | $16.55M | $15.17M |
| PP&E, net | $323,305 | $173,879 | $201,514 | $229,376 | $268,911 | $308,642 | $348,373 | $388,180 |
| Goodwill | $15.79M | $14.19M | $14.19M | $14.19M | $16.22M | $16.22M | $16.22M | $16.22M |
| Intangibles | $2.99M | $2.95M | $2.70M | $2.50M | $2.24M | $2.02M | $1.89M | $1.62M |
| Total assets | $38.73M | $32.76M | $30.13M | $30.46M | $52.78M | $54.23M | $58.06M | $57.33M |
| Current liabilities | $36.55M | $39.41M | $32.20M | $29.78M | $32.74M | $42.40M | $46.23M | $38.05M |
| Short-term debt | $16.70M | $19.21M | $15.17M | $10.89M | $12.21M | $13.18M | $17.71M | $11.93M |
| Long-term debt | $1.46M | $12.60M | $12.60M | $12.60M | $12.60M | $10.10M | $24.12M | $11.46M |
| Total debt | $18.16M | $31.81M | $27.77M | $23.49M | $24.81M | $23.28M | $41.84M | $23.38M |
| Total liabilities | $38.56M | $52.26M | $45.19M | $42.91M | $46.00M | $53.32M | $53.58M | $50.60M |
| Shareholders' equity | -$1.70M | -$19.50M | -$15.06M | -$12.45M | $6.78M | $905,255 | $4.48M | $6.73M |
| Net debt | $17.69M | $29.35M | $27.72M | $23.44M | $20.58M | $22.86M | $39.32M | $22.35M |
| Shares outstanding | 4.73M | 2.84M | 119.40M | 2.03M | 89.45M | 63.14M | 61.46M | 51.06M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.90M | -$2.89M | -$3.41M | -$6.29M | -$1.14M | -$2.08M | -$1.35M | -$2.62M |
| Investing cash flow | $723,195 | -$242,132 | -$205,098 | -$255,382 | -$221,085 | -$131,926 | -$273,133 | $802,554 |
| Financing cash flow | $200,000 | $5.54M | $3.63M | $2.36M | $5.17M | $114,281 | $3.11M | $2.06M |
| Depreciation & amortization | $356,421 | $356,597 | $356,824 | $802,602 | $802,794 | $802,796 | $802,872 | $647,241 |
| Stock-based compensation | $2.04M | $1.20M | $1.36M | $355,698 | $25.72M | $935,222 | $27.77M | — |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.